Exact Mass: 474.0973288
Exact Mass Matches: 474.0973288
Found 34 metabolites which its exact mass value is equals to given mass value 474.0973288,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
C23H23ClN2O5S (474.10161380000005)
3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
C23H23ClN2O5S (474.10161380000005)
Rilmazafone
Hyperxanthone|Hypholomin A|Hypholomin-A|Hypholomine A
Ki16425
C23H23ClN2O5S (474.10161380000005)
Vandetanib
C22H24BrFN4O2 (474.10665559999995)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
Cys Cys Cys Phe
C18H26N4O5S3 (474.10652660000005)
Cys Cys Phe Cys
C18H26N4O5S3 (474.10652660000005)
Cys Phe Cys Cys
C18H26N4O5S3 (474.10652660000005)
Phe Cys Cys Cys
C18H26N4O5S3 (474.10652660000005)
Rilmazafone
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic
Benzeneacetic acid, 4-chloro-a-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]benzo[b]thien-6-yl]oxy]-, methyl ester
C23H23ClN2O5S (474.10161380000005)
METHYL3,4-DI[[(4-METHYLPHENYL)SULFONYL]AMINO]BENZOATE
6-Chloro-2-oxo-4-methylchromen-7-yl 4-O-beta-D-xylopyranosyl-beta-D-xylopyranoside
N-(4-CHLORO-2-METHYLPHENYL)-2-(N-(3,4-DIMETHOXYPHENYL)PHENYLSULFONAMIDO)ACETAMIDE
C23H23ClN2O5S (474.10161380000005)
BIS(2-(4-AZIDOSALICYLAMIDO)ETHYL) DISULF
C18H18N8O4S2 (474.08923880000003)
5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide
3-[({4-[4-({[(1S)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
C23H23ClN2O5S (474.10161380000005)
3-[({4-[4-({[(1R)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
C23H23ClN2O5S (474.10161380000005)
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)piperidine-3-carboxamide
GluN2B-NMDAR antagonist-1
GluN2B-NMDAR antagonist-1 is an orally active GluN2B-NMDAR antagonist. GluN2B-NMDAR antagonist-1 has neuroprotective activity. GluN2B-NMDAR antagonist-1 can be used for research of ischemic injury[1].